ALLO
Allogene Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 78 | -4 | 183.62M | $382.24M | +6 | −10 |
| Q1 2026 | 84 | +8 | 106.47M | $259.25M | +11 | −3 |
| Q4 2025 | 76 | +2 | 91.09M | $124.76M | +2 | — |
| Q3 2025 | 16 | 0 | 74.87M | $92.84M | +1 | −1 |
| Q2 2025 | 13 | 0 | 69.68M | $78.74M | — | — |
| Q1 2025 | 10 | +1 | 41.70M | $60.89M | +2 | −1 |
| Q4 2024 | 9 | -2 | 35.46M | $75.54M | — | −2 |
| Q3 2024 | 10 | 0 | 29.49M | $82.58M | — | — |
| Q2 2024 | 10 | — | 28.78M | $67.06M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Capital World Investors ✦ | 6.90M | — | $16.07M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 5.79M | — | $13.49M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 5.79M | — | $13.49M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | PRIMECAP Management ✦ | 5.67M | — | $13.21M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Two Sigma Investments ✦ | 2.96M | — | $6.90M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 2.82M | — | $6.57M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 2.82M | — | $6.57M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 2.45M | — | $5.70M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 2.45M | — | $5.70M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Renaissance Technologies ✦ | 1.75M | — | $4.07M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 240.25K | — | $559,794 | 0.0% | n/c | 1 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 240.25K | — | $559,794 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Millennium Management ✦ | 179.62K | — | $418,524 | 0.0% | n/c | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 27.29K | — | $63,579 | 0.0% | n/c | 1 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 27.29K | — | $63,579 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 207 holders, 182.71M shares, $425.90M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 29.70K sh · $62,958
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology